Lithium as an adjuvant of iodine-131 uptake when treating patients with well-differentiated thyroid carcinoma.
Differences in the I-131 uptake by 14 metastatic lesions from well-differentiated thyroid carcinoma and 12 local remnants of normal thyroid tissue before and after an adjuvant therapy with lithium carbonate, were observed. After the adjuvant treatment and administration of an I-131 tracer dose, a considerable increase of radioiodine uptake in all metastatic lesions was found (P less than 0.001), but only a slight increase was found in 50% of the normal tissue. The response to lithium carbonate by neoplastic tissue seems to be different than that of the normal thyroid tissue, and produces a lengthening of the average I-131 biologic life that could be helpful when treating well-differentiated thyroid carcinoma.
D000230:Adenocarcinoma / Q000532:radiotherapy*; D000277:Adjuvants, Pharmaceutic; D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes / Q000008:administration & dosage* / Q000627:therapeutic use; D008094:Lithium / Q000008:administration & dosage* / Q000627:therapeutic use; D016651:Lithium Carbonate; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis / Q000000981:diagnostic imaging; D011877:Radionuclide Imaging; D013964:Thyroid Neoplasms / Q000532:radiotherapy*
D000277:Adjuvants, Pharmaceutic; D007457:Iodine Radioisotopes; D016651:Lithium Carbonate; D008094:Lithium